Form 4: Janux Therapeutics Executive Sells 50,000 Shares After Exercising Stock Options
SEC Form 4 Filing
Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, sold 50,000 shares of common stock on September 27, 2024, after exercising stock options.
Summary
- Andrew Hollman Meyer, the Chief Business Officer of Janux Therapeutics, executed a transaction involving the company's stock on September 27, 2024.
- Meyer exercised options to acquire 50,000 shares of common stock at a price of $4.21 per share.
- Simultaneously, Meyer sold 50,000 shares of common stock at a weighted average price of $45.9551, with prices ranging from $45.55 to $46.50.
- Following these transactions, Meyer directly owns 67,592 shares of Janux Therapeutics.
- Meyer also holds options to purchase 100,667 shares of Janux Therapeutics stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The sentiment is neither particularly positive nor negative as it reflects routine transactions.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may interpret the sale of shares by a key executive as a signal, although it is common for executives to sell shares acquired through stock options for personal financial management.
Key Dates
| Date | Description |
|---|---|
| November 15, 2021 | Meyer acquired 1,189 shares under the Issuer's 2021 Employee Stock Purchase Plan. |
| May 13, 2022 | Meyer acquired 1,752 shares under the Plan. |
| May 15, 2023 | Meyer acquired 2,401 shares acquired under the Plan. |
| May 15, 2024 | Meyer acquired 2,834 shares acquired under the Plan. |
| 09/27/2024 | Meyer exercised stock options and sold 50,000 shares of Janux Therapeutics stock. |
| 03/09/2031 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.